BioSpace News Archive

Individuals can purchase COVID-19 antibody testing for themselves online, without visiting a doctor’s office, through QuestDirect, the consumer-initiated testing business of Quest Diagnostics, the world’s leading provider of diagnostic information services.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it is now authorized by the Polish Department of Registration of

In response to the novel coronavirus (SARS-CoV-2), Shionogi & Co., Ltd. (hereafter “Shionogi”), a pharmaceutical company with a major focus on infectious diseases, has joined the ranks of pharmaceutical companies across the globe and is working with public institutions, academia and partner companies in the following efforts to fight against COVID-19: Commitment to the discovery of novel

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an upd

Preparations for the Manufacturing of GMP Vaccine at Emergent BioSolutions Ongoing Vaxart is Participating in Maxim’s Infectious Disease Virtual Conference on May 5, 2020 SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today provided an update on its financials for the first quarter of 2020, and a corporate update ahead of its

InterShunt Technologies, Inc., an early stage medical device company developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients, announced the formation of a Scientific Advisory Board and successful first meeting.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that Brian Varnum , Ph.D., President and Chief Development Officer, will participate in a panel discussion on

New Indian regulatory approval received for its cryoablation technology to destroy tumors in extensive indications, including for breast, lung, bone and kidney cancer

Target Selector™ assay kits enable assay developers to leverage Biocept’s patented, high-sensitivity technology for the detection of key actional oncogene mutations from both tissue biopsies and blood for liquid biopsy uses

AtaCor Medical, Inc. announced that is has completed a $25M Series B financing.